BIOMAT Database Logo BIOMAT Database Logo

A multicenter study of sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: executive summary. 1990

D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth

UI MeSH Term Description Entries
D007319 Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition. Disorders of Initiating and Maintaining Sleep,Insomnia,Sleeplessness,Chronic Insomnia,DIMS (Disorders of Initiating and Maintaining Sleep),Early Awakening,Insomnia Disorder,Nonorganic Insomnia,Primary Insomnia,Psychophysiological Insomnia,Rebound Insomnia,Secondary Insomnia,Sleep Initiation Dysfunction,Transient Insomnia,Awakening, Early,Dysfunction, Sleep Initiation,Dysfunctions, Sleep Initiation,Insomnia Disorders,Insomnia, Chronic,Insomnia, Nonorganic,Insomnia, Primary,Insomnia, Psychophysiological,Insomnia, Rebound,Insomnia, Secondary,Insomnia, Transient,Insomnias,Sleep Initiation Dysfunctions
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005479 Flurazepam A benzodiazepine derivative used mainly as a hypnotic. Apo-Flurazepam,Dalmadorm,Dalmane,Dormodor,Flurazepam Dihydrochloride,Flurazepam Hydrochloride,Flurazepam Mono-Perchlorate,Flurazepam Monohydrochloride,Staurodorm,Apo Flurazepam,Dihydrochloride, Flurazepam,Flurazepam Mono Perchlorate,Hydrochloride, Flurazepam,Mono-Perchlorate, Flurazepam,Monohydrochloride, Flurazepam
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000339 Affect The feeling-tone accompaniment of an idea or mental representation. It is the most direct psychic derivative of instinct and the psychic representative of the various bodily changes by means of which instincts manifest themselves. Mood,Affects,Moods
D001143 Arousal Cortical vigilance or readiness of tone, presumed to be in response to sensory stimulation via the reticular activating system. Vigilance, Cortical,Arousals,Cortical Vigilance

Related Publications

D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: methodology.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: an introduction.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Psychomotor performance in chronic insomniacs during 14-day use of flurazepam and midazolam.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Clinical safety of flurazepam and midazolam during 14-day use in chronic insomniacs.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Characteristics of chronic insomniacs examined in a multicenter 14-day study of flurazepam and midazolam.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
A multicenter 14-day study of flurazepam and midazolam in chronic insomniacs: general discussion and conclusions.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Effects of flurazepam and midazolam on sleep and next-day performance in chronic insomniacs: report of a multicenter study.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Plasma concentrations of flurazepam and midazolam in chronic insomniacs during 14-day use and their relationship to therapeutic effects and next-day performance and mood.
August 1990, Journal of clinical psychopharmacology,
D Chen, and D A Chernik, and E Ellinwood, and P Hauri, and L C Johnson, and L L Judd, and D F Kripke, and M Linnoila, and H Moskowitz, and T Roth
Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam.
August 1990, Journal of clinical psychopharmacology,
Copied contents to your clipboard!